• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The comparison of serum visfatin levels in patients with acute PTE and non-PTE independent of BMI
Conclusions: Although the serum visfatin levels were lower in the acute PTE group than in the non-PTE group both of which had similar BMI, the difference was not statistically significant. Further and larger studies are needed to evaluate the visfatin levels in acute PTE.
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Tutar, N., Dogan, S., Buyukoglan, H., Sen, A., Yilmaz, I., Yildirim, A., Dogan, A., Yetkin, A., Oymak, F. s., Gulmez, I., Demir, R. Tags: 4.3 Pulmonary Circulation and Pulmonary Vascular Disease Source Type: research

Rivaroxaban in non valvular atrial fibrillation: subgroups analysis.
Authors: Greco C Abstract After the ROCKET AF study main paper several subgroups analysis were recently published. These studies are useful to better evaluate the rivaroxaban efficacy and safety in different clinical conditions. Here the subgroup analysis of patients with moderate renal failure, heart failure and diabetes are presented. Post hoc data on patients who underwent an electrical or pharmacological cardioversion during ROKET AF follow up were available and here we analyze also the results of the first randomized study on electrical cardioversion in patients treated with new oral anticolagulants: the X-VeR...
Source: Monaldi Archives for Chest Disease - December 21, 2015 Category: Respiratory Medicine Tags: Monaldi Arch Chest Dis Source Type: research

Dealing with surgical left ventricular assist device complications.
Authors: Kilic A, Acker MA, Atluri P Abstract Left ventricular assist devices (LVAD) will undoubtedly have an increasing role due to the aging population, anticipated concomitant increase in the prevalence of end-stage heart failure, and improvements in LVAD technology and outcomes. As with any surgical procedure, LVAD implantation is associated with an adverse event profile. Such complications of LVAD therapy include bleeding, infection, pump thrombosis, right heart failure, device malfunction, and stroke. Although each has a unique management, early recognition and diagnosis of these complications is uniformly pa...
Source: Journal of Thoracic Disease - January 24, 2016 Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research

New anticoagulants for the treatment of venous thromboembolism
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in p...
Source: Jornal Brasileiro de Pneumologia - May 6, 2016 Category: Respiratory Medicine Source Type: research

Bronchial thermoplasty in a patient with difficult-to-control asthma
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in p...
Source: Jornal Brasileiro de Pneumologia - May 6, 2016 Category: Respiratory Medicine Source Type: research

HRCT in smoking-related interstitial lung diseases: a kaleidoscopic overlap of patterns
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in p...
Source: Jornal Brasileiro de Pneumologia - May 6, 2016 Category: Respiratory Medicine Source Type: research

Pre-operative evaluation in obstructive sleep apnea patients undergoing bariatric surgery: sleep laboratory limitations
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in p...
Source: Jornal Brasileiro de Pneumologia - May 6, 2016 Category: Respiratory Medicine Source Type: research

Open letter to city, state, and federal health authorities, to State Health Councils, and to the National Council of Municipal Health Secretaries in Brazil
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in p...
Source: Jornal Brasileiro de Pneumologia - May 6, 2016 Category: Respiratory Medicine Source Type: research

Interlobular septal thickening
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in p...
Source: Jornal Brasileiro de Pneumologia - May 6, 2016 Category: Respiratory Medicine Source Type: research

What is the importance of calculating sample size?
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in p...
Source: Jornal Brasileiro de Pneumologia - May 6, 2016 Category: Respiratory Medicine Source Type: research

Risk of cardiovascular comorbidities in patients with idiopathic pulmonary fibrosis: Analysis of Medicare data
Conclusions: Newly diagnosed IPF pts are typically sicker than non-IPF pts and have significantly higher rates of CV conditions. The higher rate of CV conditions needs to be taken into consideration for the management and treatment of pts with IPF.
Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Broder, M., Change, E., Papoyan, E., Popescu, I., Reddy, S., Raimundo, K., Chou, W., Stauffer, J. Tags: 6.1 Epidemiology Source Type: research

Reversal of Direct Oral Anticoagulants: Current Status and Future Directions
Semin Respir Crit Care Med 2017; 38: 040-050 DOI: 10.1055/s-0036-1597831Direct oral anticoagulants (DOACs) are increasingly used for prevention and treatment of venous thromboembolism and for prevention of stroke in patients with nonvalvular atrial fibrillation. In phase III clinical trials that included more than 100,000 patients, the DOACs were at least as effective as vitamin K antagonists (VKAs) and were associated with less serious bleeding, particularly less intracranial bleeding. Real-world evidence supports these outcomes. Despite this, some physicians and patients are concerned about serious bleeding or emergencie...
Source: Seminars in Respiratory and Critical Care Medicine - February 15, 2017 Category: Respiratory Medicine Authors: Weitz, Jeffrey I. Tags: Review Article Source Type: research

Massive Pulmonary Embolism: Extracorporeal Membrane Oxygenation and Surgical Pulmonary Embolectomy
Semin Respir Crit Care Med 2017; 38: 066-072 DOI: 10.1055/s-0036-1597559Massive pulmonary embolism (PE) refers to large emboli that cause hemodynamic instability, right ventricular failure, and circulatory collapse. According to the 2016 ACCP Antithrombotic Guidelines, therapy for massive PE should include systemic thrombolytic therapy in conjunction with anticoagulation and supportive care. However, in patients with a contraindication to systemic thrombolytics or in those who fail the above interventions, extracorporeal membrane oxygenation (ECMO) and/or surgical embolectomy may be used to improve oxygenation, achieve hem...
Source: Seminars in Respiratory and Critical Care Medicine - February 15, 2017 Category: Respiratory Medicine Authors: Weinberg, Aaron Tapson, Victor F. Ramzy, Danny Tags: Review Article Source Type: research

Systemic blood pressure trends and antihypertensive utilization following continuous-flow left ventricular assist device implantation: an analysis of the interagency registry for mechanically assisted circulatory support.
Conclusions: SBP rises rapidly after CF-LVAD implantation, stabilizing after 3 months, and is matched by concomitant changes in AH utilization; this AH use has increased over consecutive implant years. PMID: 29997951 [PubMed]
Source: Journal of Thoracic Disease - July 14, 2018 Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research

Pages: 1  2  3  4  5  6